Search Result
Results for "
Antibody-drug Conjugate/Targets
" in MedChemExpress (MCE) Product Catalog:
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-102001
-
|
|
ADC Cytotoxin
|
Cancer
|
|
Tomaymycin DM, a DNA alkylator, is a derivative of Tomaymycin, it is a PBD dimer, which is attached to tumor targeting antibodies to create antibody-drug conjugates (ADCs).
|
-
-
- HY-132254
-
|
IMMU-132
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity .
|
-
-
- HY-135125
-
|
|
ADC Cytotoxin
|
Cancer
|
|
DC4, an ADC cytotoxin, can be used in the synthesis of antibody-drug conjugate (ADC). DC4 can be used for the targeted treatment of cancer .
|
-
-
- HY-141594
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Modified MMAF, an ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC). Modified MMAF can be used for the targeted research of cancer .
|
-
-
- HY-132259
-
|
ABT-414
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used for cancer research .
|
-
-
- HY-132254A
-
|
IMMU-132 (solution)
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity .
|
-
-
- HY-112899
-
|
|
ADC Cytotoxin
DNA Alkylator/Crosslinker
|
Cancer
|
|
DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is a ADC Cytotoxin. DC1 can be used in synthesis of antibody-drug conjugates for the targeted treatment of cancer.
|
-
-
- HY-P99854
-
-
-
- HY-P99788
-
|
|
ADC Antibody
ALCAM/CD166
|
Cancer
|
|
Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers .
|
-
-
- HY-148128
-
|
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .
|
-
-
- HY-P99733
-
|
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .
|
-
-
- HY-P99352
-
|
Anti-MSLN Antibody
|
Mesothelin
|
Cancer
|
|
Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor .
|
-
-
- HY-160182
-
-
-
- HY-152963
-
|
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF). Tisotumab vedotin consists of a fully human monoclonal antibody to tissue factor (TF-011) conjugated to Monomethyl Auristatin E (MMAE). Tisotumab vedotin has good antitumor activity and can be used in the research of advanced or metastatic solid tumors .
|
-
-
- HY-P9921
-
|
Ado-Trastuzumab emtansine; PRO132365; T-DM 1
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .
|
-
-
- HY-P9921A
-
|
Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .
|
-
-
- HY-P99734
-
|
ADCT-601
|
TAM Receptor
|
Cancer
|
|
Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers .
|
-
-
- HY-P99042
-
|
|
ADC Antibody
|
Cancer
|
|
Polatuzumab is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab can be used to synthesize Polatuzumab Vedotin, which is an antibody-drug conjugate (ADC) targeting CD79b .
|
-
-
- HY-141601
-
|
ABBV-399
|
Antibody-Drug Conjugates (ADCs)
c-Met/HGFR
|
Cancer
|
|
Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used in cancer research .
|
-
-
- HY-145951
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Amidate-VC-PAB-MMAF consists a cleavable ADC linker (Amidate-VC-PAB) and a potent tubulin polymerization inhibitor (MMAF). Amidate-VC-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs). Amidate-VC-PAB-MMAF reduces off-target cytotoxicity of ADCs .
|
-
-
- HY-P99264
-
|
Humanized Anti-CD22 Recombinant Antibody
|
ADC Antibody
CD22
|
Cancer
|
|
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
|
-
-
- HY-141662
-
|
|
STING
Drug-Linker Conjugates for ADC
|
Inflammation/Immunology
Cancer
|
|
2’,3’-cGAMP-C2-PPA is a cyclic dinucleotide interferon gene-stimulating protein (STING) agonist. 2’,3’-cGAMP-C2-PPA is a drug conjugated conjugate used to target antibody-drug conjugated conjugate (ADC) for the treatment of cancer. 2’,3’-cGAMP-C2-PPA can be used in the study of immune and tumor-related diseases .
|
-
-
- HY-122534
-
|
|
Mitochondrial Metabolism
ADC Cytotoxin
Apoptosis
|
Cancer
|
|
Mensacarcin, a highly complex polyketide, strongly inhibits cell growth universally in cancer cell lines and potently induces apoptosis in melanoma cells. Mensacarcin targets to mitochondria, affects energy metabolism in mitochondria, and activates caspase-dependent apoptotic pathways. Mensacarcin, an antibiotic, can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .
|
-
-
- HY-132253
-
|
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
-
- HY-P99843
-
|
|
TROP2
ADC Antibody
|
Cancer
|
|
Datopotamab (CDP7657) is an antibody targeting to TROP2. Datopotamab can be used to synthesize Datopotamab deruxtecan (HY-141598), TROP2-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan consists of DNA topoisomerase I inhibitor Deruxtecan (HY-13631E) and Datopotamab .
|
-
-
- HY-135124
-
|
|
ADC Cytotoxin
|
Cancer
|
|
DC44SMe, a phosphate proagent of cytotoxic DNA alkylator DC44, can be used in the synthesis of antibody-drug conjugate (ADC). DC44SMe exhibits IC50s of 2.0 nM, 2.8 nM, and 1.9 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively. DC44SMe can be used for the targeted treatment of cancer .
|
-
-
- HY-135123
-
|
|
ADC Cytotoxin
|
Cancer
|
|
DC4SMe, a phosphate proagent of cytotoxic DNA alkylator DC4, can be used in the synthesis of antibody-drug conjugate (ADC). DC4SMe exhibits IC50s of 1.9 nM, 2.9 nM, and 1.8 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively. DC4SMe can be used for the targeted treatment of cancer .
|
-
-
- HY-112898
-
|
|
ADC Cytotoxin
|
Cancer
|
|
DC1Sme, a DC1 derivative, exhibits IC50 values of 22 pM, 10 pM, 32 pM and 250 pM for Ramos, Namalwa, HL60/s and COLO 205 cancer cells, respectively. DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is a ADC Cytotoxin. DC1 can be used in synthesis of antibody-drug conjugates for the targeted treatment of cancer.
|
-
-
- HY-P99971
-
|
|
ADC Antibody
|
Cancer
|
|
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .
|
-
-
- HY-P990027
-
|
|
ADC Antibody
|
Cancer
|
|
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .
|
-
-
- HY-153360
-
|
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .
|
-
-
- HY-P99740
-
|
|
CD276/B7-H3
|
Cancer
|
|
Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclax (HY-137774), an BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
|
-
-
-
HY-L023
-
|
|
92 compounds
|
|
Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.
The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 92 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99054
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative) .
|
-
- HY-P99854
-
-
- HY-P99788
-
|
|
ADC Antibody
ALCAM/CD166
|
Cancer
|
|
Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers .
|
-
- HY-P99352
-
|
Anti-MSLN Antibody
|
Mesothelin
|
Cancer
|
|
Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor .
|
-
- HY-P99733
-
|
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .
|
-
- HY-P99734
-
|
ADCT-601
|
TAM Receptor
|
Cancer
|
|
Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers .
|
-
- HY-P99042
-
|
|
ADC Antibody
|
Cancer
|
|
Polatuzumab is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab can be used to synthesize Polatuzumab Vedotin, which is an antibody-drug conjugate (ADC) targeting CD79b .
|
-
- HY-P99264
-
|
Humanized Anti-CD22 Recombinant Antibody
|
ADC Antibody
CD22
|
Cancer
|
|
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
|
-
- HY-132253
-
|
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-P99843
-
|
|
TROP2
ADC Antibody
|
Cancer
|
|
Datopotamab (CDP7657) is an antibody targeting to TROP2. Datopotamab can be used to synthesize Datopotamab deruxtecan (HY-141598), TROP2-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan consists of DNA topoisomerase I inhibitor Deruxtecan (HY-13631E) and Datopotamab .
|
-
- HY-P99971
-
|
|
ADC Antibody
|
Cancer
|
|
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .
|
-
- HY-P990027
-
|
|
ADC Antibody
|
Cancer
|
|
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .
|
-
- HY-P99740
-
|
|
CD276/B7-H3
|
Cancer
|
|
Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclax (HY-137774), an BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
